Table 2 Procedural parameters and outcome.

From: The impact of ultra-high-density mapping on long-term outcome after catheter ablation of ventricular tachycardia

 

Total (n = 122)

Ultra-high-density mapping (n = 61)

Conventional 3D-mapping (n = 61)

P value

A. Procedural parameters

Procedure duration, min

198.0 (160.0–240.0)

201.5 (175.8–240.0)

180.0 (145.0–235.0)

0.117

Fluoroscopy duration, min

20.0 (14.8–29.5)

19.0 (15.2–26.0)

22.9 (13.8–31.1)

0.481

Radio frequency duration, sec

1639 (963–2401)

1637 (871–2536)

1641 (1096–2333)

0.763

 

Total (n = 122)

Ultra-high-density mapping (n = 61)

Conventional 3D-mapping (n = 61)

P value

B. Long-term outcome

Median survival time free from recurrence or death from any cause, months

 

15.8 [6.8–24.3]

5.1 [2.5–15.7]

 

Cumulative incidence of recurrence or disease-related death at 12 months, %

 

41.0 [28.5–53.1]

59.0 [45.5–70.3]

 

Cumulative incidence of recurrence or disease-related death at 24 months, %

 

52.4 [36.9–65.7]

69.6 [55.9–79.8]

 

AAD at 24 months, n (%)

118 (96.7)

59 (96.7)

59 (96.7)

1.000

  Betablockers

110 (90.2)

52 (85.2)

58 (95.1)

0.1258

  Amiodarone

65 (53.3)

33 (54.0)

32 (52.5)

1.000

  Mexiletine

2 (1.6)

0

2 (3.3)

0.4959

  Calcium channel blockers

2 (1.6)

0

2 (3.3)

0.4959

  1. Unless noted, values are median [IQR], cumulative incidence estimates [95% confidence interval] or n (percent). P Value < 0.05 is considered significant. AAD indicates antiarrhythmic drug therapy; min, minutes; sec, seconds; 3D, three-dimensional.
Back to article page